BCLI – Type A Meeting with FDA
A "Type A" meeting, in this case, to discuss the contents of a refusal to file letter previously issued regarding the company's New Biologics License Application (BLA) for NurOwn® for the treatment of ALS. While this event is not one that would normally include a "runup" and an "event" type trade, the "Afterglow" traders here […]